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Abstract
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma 
(BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup 
medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous 
exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a 
vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating 
cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures 
were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while 
their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this 
self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical 
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WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor 
was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an on-target 
manner, leading to increased survival. Our results imply that the tumor-propagating cells driving 
the growth of bulk SHH-dependent MB are themselves WNT dependent. Further, our data suggest 
combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with 
SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients 
treated with vismodegib.
INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor of childhood.1 While the 
bulk of patients respond to multimodal therapy (surgery, radiation and cytotoxic 
chemotherapy), treatment-induced morbidity leaves survivors with significant 
neurocognitive and endocrine disabilities.2 These patients thus require therapies that promise 
to be more effective and less toxic. The classification of MB into four molecular 
subgroups3,4 provided a template with which to begin identifying and testing such targeted 
therapies.5,6 The best characterized subgroup is driven by the SONIC HEDGEHOG (SHH) 
signaling pathway, most commonly via mutation and loss of the gene encoding the SHH 
receptor PATCHED (PTCH). The SHH inhibitor vismodegib targets the upstream signaling 
component SMOOTHENED (SMO) and is FDA-approved for advanced basal cell 
carcinoma,7 which is almost uniformly driven by SHH signaling.8,9 As similar SMO 
inhibitors effectively target SHH-dependent mouse models of MB, significantly reducing the 
bulk of such tumors,10 they are now being tested in SHH-subgroup MB patients.11–13
Tumors are heterogeneous, comprised of immune, stromal and tumor cells proper. Even the 
tumor cells themselves show significant variation in morphologies, proliferation rates and 
self-renewing capacity.14,15 This heterogeneity is thought to result from a hierarchical 
organization, in which a small population of relatively quiescent, long-lived, multipotent, 
propagating/initiating cells drives the production of a population of rapidly amplifying 
progenitor cells, which in turn can give rise to more differentiated cell types.16 Although the 
progenitor cells constitute the bulk of the tumor, they have limited self-renewing capacity, 
and are thus maintained by the smaller population of tumor-propagating cells. The tumor-
propagating cells are relatively chemotherapy resistant, and are therefore thought to drive the 
tumor recurrence often observed in patients treated with chemotherapy.17 Similarly, while 
limited clinical experience with SMO inhibitors in clinical trials has shown that there is 
often a rapid initial response to vismodegib, this is frequently followed by aggressive 
recurrent MB growth.11,18 Additionally, it was noted that basal cell carcinoma patients often 
exhibited rapid recurrence upon vismodegib cessation, consistent with such tumors 
harboring a reservoir of vismodegib-resistant cells capable of driving recurrence.19–22
A number of tumor-propagating cells have been described for the SHH-subgroup of MB, 
with distinct properties, biomarkers, sensitivity to SMO inhibitors and abilities to be 
propagated as neurospheres ex vivo.23–28 Most recently, lineage tracing in a mouse model of 
SHH MB identified a small population of SOX2+ MB propagating cells (MPCs), and a 
population of SOX2− cells that constituted the bulk of the tumor proper.28,29 The SOX2+ 
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cells were capable of efficient self-renewal but resistant to vismodegib, while the SOX2− 
cells exhibited a more limited capacity for self-renewal but were sensitive to vismodegib. 
Consistent with this observation, treatment of this mouse model of MB with vismodegib led 
to an enrichment of SOX2+ cells in the residual tumor.28 These SOX2+ cells may contribute 
to recurrence observed in patients treated with vismodegib. Here, we show that self-renewal 
of SOX2+ enriched sphere cultures (SCs) is dependent on canonical WNT activity, and that 
loss of Trp53 drives this WNT dependence. A small molecule WNT inhibitor also depleted 
this population of SOX2+ cells in SHH-subgroup MB in vivo, significantly reducing the 
ability of SHH tumors to propagate.
RESULTS
Characterization of MB sphere cultures
SHH-subgroup MBs harbor a small and phenotypically primitive population of MPCs that 
are enriched in cultured neurospheres ex vivo.25,27 We isolated and characterized the MPC-
like characteristics of three independent Ptch1−/−-;Trp53−/− neurosphere cultures (SC 1–3). 
These cultures were enriched for neural stem cell markers, such as Nestin and Sox2, relative 
to bulk MB tissue (Figure 1a). They also displayed the cellular heterogeneity previously 
described for MPCs enriched cultures,25,30 as evidenced by the mutually exclusive staining 
of a neural stem cell marker (NESTIN) with that of a neuronal progenitor marker (β3-
TUBULIN) (Figure 1b). The SCs could be induced to express biomarkers of three distinct 
neural lineages (Figure 1c), suggesting that they are also pluripotent. Consistent with them 
being enriched for tumor-propagating cells, as few as 5000 SC cells were able to form 
tumors when implanted into mice (Figure 1d). SOX2 has previously being described as a 
biomarker for such tumor-propagating cells.28,29 We therefore quantitated the percentage of 
SOX2+ cells in the SCs relative to that in primary MB tissue. SOX2+ cells were considerably 
more enriched in the SCs, relative to the approximate 5% of such cells observed in primary 
MB (Figure 1e).
The self-renewal of MPCs is dependent on WNT activity
The MPC enriched SCs were exposed to the SMO inhibitors cyclopamine and vismodegib, 
the inactive cyclopamine analog tomatidine, or a vehicle control. Interestingly, even though 
the parental MB tissue responded to vismodegib in vivo (Supplementary Figure S1A), 
neither SMO inhibitor had significant effects on the cellular viability (Supplementary 
Figures S1B,C) or self-renewal (Supplementary Figures S1D,E) of the three SCs. However, 
they both attenuated SHH target gene expression (Supplementary Figures S1F,G,H) relative 
to either a vehicle control or cultures treated with tomatidine. These results suggest that 
SMO inhibitors are capable of attenuating SHH signaling, but that such attenuation has only 
minimal biological affects in these Trp53-deficient SCs.
A WNT-driven gene expression profile was previously observed in Ptch1+/−;Trp53−/− SCs.27 
Further, SOX2 expression, for which the SCs are enriched (Figure 1e), is WNT-dependent in 
many physiological settings.31 Thus, we hypothesized that the MB SCs we had isolated were 
WNT-dependent. Consistent with this hypothesis, SCs were enriched for WNT signaling 
biomarkers relative to primary MB (Figure 2a). To directly test whether SCs are WNT-
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dependent we transfected them with pools of siRNA targeting the pivotal WNT signaling 
component β-Catenin (Ctnnb1), green fluorescent protein (GFP), or a scrambled control 
siRNA. Relative to the control siRNAs, the Ctnnb1 siRNA reduced the expression of the 
WNT biomarker Lgr5 as well as Sox2, but had no effect on the SHH target genes Gli1 or 
Ptch2 (Figure 2b). Further, the Ctnnb1 siRNA attenuated the self-renewal capability of the 
SCs (Figure 2c), but had little effect on the overall viability of these cultures (Supplementary 
Figure S2A). Although WNT activation in MB is commonly linked to Ctnnb1 
mutations,32,33 no Ctnnb1 mutations were identified in the SCs (Supplementary Figure 
S2B). As β-CATENIN also plays an essential role in E-CADHERIN signaling, distinct from 
its role in WNT signaling,34 we also utilized a dominant negative form of the WNT 
transcription factor TCF3 (dnTCF3) commonly used to definitively identify WNT-dependent 
biomarkers.35 Cultures expressing dnTCF3 exhibited significantly attenuated WNT target 
gene expression, including Sox2, but had no effect on the expression of two SHH target 
genes (Figure 2d). SCs expressing dnTCF3 had a reduced capacity for self-renewal (Figure 
2e), but exhibited no change in viability (Figure 2f). To examine if the WNT activation we 
observe in SCs is ligand-driven we overexpressed a negative regulator of the canonical WNT 
pathway, DKK1, which antagonizes the LRP5/6 WNT co-receptor.36 Overexpression of 
DKK1 downregulated WNT target gene expression (Figure 2g), and reduced secondary 
sphere formation (Figure 2h) without affecting cell viability (Figure 2i). Combined, these 
results suggest that WNT signaling plays an important role in the self-renewal of the SCs, 
but a more minimal role in the immediate viability of these cultures. Consistent with this 
suggestion, two small-molecule activators of WNT signaling (GSK-3β inhibitors)37 
significantly increased the self-renewal capacity of these SCs (Supplementary Figure S2C).
Small-molecule WNT inhibitors attenuate the self-renewal of MPCs To identify a small-
molecule WNT inhibitor that could be used to attenuate MB growth in vivo, we screened a 
number of mechanistically distinct small-molecule WNT inhibitors for their ability to 
attenuate self-renewal ex vivo. As downregulation of WNT signaling by DKK1 
overexpression reduced secondary sphere formation (Figure 2h), and DKK1 acts to suppress 
ligand-dependent WNT signaling,36 we tested a small-molecule that directly attenuates 
WNT ligand activity, the PORCUPINE inhibitor LGK974.38 Similar to DKK1 
overexpression, PORCUPINE inhibition reduced WNT pathway activation (Figure 3a) and 
secondary sphere formation (Figure 3b), without affecting SC viability (Figure 3c). 
Consistent with this WNT activation being ligand driven, Wnt7a and Wnt7b were highly 
expressed in SCs relative to parental MB tissue (Supplementary Figure S3A).
As both Ctnnb1 knockdown (Figure 2c) and overexpression of dnTCF reduced secondary 
sphere formation (Figure 2e), we included in our screening antagonists of the TCF/β-
CATENIN complex: carnosate,39 CCT-031374,40 ICG-00141 and PKF115-584.42 We first 
confirmed that this panel of TCF/β-CATENIN antagonists reduced WNT activity in a WNT-
dependent reporter assay (Supplementary Figure S3B). We next treated SCs with these 
antagonists and observed a significant reduction in secondary sphere formation (Figure 3d), 
which occurred at lower doses than those that had effects on SC viability (Figure 3e). These 
WNT inhibitors also attenuated the expression of WNT target genes in SCs (Figure 3f), 
consistent with an on-target mechanism of action. We also verified that one of these 
inhibitors, carnosate, reduced the expression of Sox2 (Supplementary Figure S3C) and the 
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numbers of SOX2+ cells in these cultures (Supplementary Figure S3D). Finally, we 
determined if carnosate affects either proliferation or survival of SOX+ cells. No changes in 
the expression of either proliferation proliferating cell nuclear antigen (PCNA) or apoptotic 
(CLEAVED CASPASE-3) biomarkers were observed in SOX2+ cells (Supplementary Figure 
S3E), consistent with minimal changes in the number of viable cells in culture after longer 
exposure to WNT inhibitor (Supplementary Figure S3F). Together, these results are 
consistent with WNT signaling controlling Sox2 expression, which is required for SCs to 
self-renew.
Loss of Trp53 results in WNT-dependent self-renewal
A number of groups have previously shown that WNT activation attenuates SHH-subgroup 
MB growth,43–45 observations inconsistent with our results. These previous results were 
obtained using SmoA1- or Ptch1-driven MB mouse models, or cells derived from such mice, 
which in all cases were in a wild type (WT) Trp53 background. Thus, we hypothesized that 
the WNT requirement for SC self-renewal that we observe results from loss of Trp53. To test 
this hypothesis, we compared the expression of WNT biomarkers in Ptch1−/− SCs 
expressing WT Trp53 or deficient for Trp53. We noted that expression of WNT biomarkers, 
including WNT ligands, was significantly reduced in the SCs expressing WT Trp53 (Figure 
4a). SCs expressing WT Trp53 were unresponsive to small-molecule β-CATENIN/TCF 
inhibitors, as carnosate was unable to downregulate the expression of WNT target genes 
(Figure 4b), attenuate self-renewal (Figure 4c) or affect viability (Figure 4d). Further, 
overexpression of dnTCF3 did not attenuate WNT target gene expression (Figure 4e) or self-
renewal (Figure 4f) in WT Trp53 SCs, but did in Trp53-deficient cultures. The cell viability 
of either SC was not reduced by dnTCF3 (Supplementary Figure S4A). To more directly 
address the effects of P53 on WNT signaling we attenuated P53 activity in SCs expressing 
WT Trp53 and expressed WT Trp53 in those cultures deficient in Trp53, and determined 
P53 and WNT activity. We observed increased expression of a P53 target gene (Mdm2) and 
decreased expression of WNT target genes upon transfection of Ptch1−/− SCs deficient in 
Trp53 with a plasmid expressing WT Trp53 (Figure 4g). Conversely, reducing P53 activity 
in Ptch1−/− SCs WT for Trp53, via expression of a dominant negative Trp53 construct or 
treatment with the small-molecule P53 inhibitor [Pifithrin-α (PFTα)], reduced Mdm2 
expression but increased expression of WNT target genes (Figures 4h and i). Together, these 
results suggest that loss of Trp53 results in increased WNT activity in Ptch1 mutation-driven 
SCs.
MB growth and propagation is WNT-dependent
To examine the dependence of MB growth and initiation on WNT signaling in vivo, we 
implanted Trp53 mutant, Ptch1-driven MB tissue, which had never been cultured ex vivo, 
into the brains of immunocompromised mice and treated them with vehicle or carnosate. 
Carnosate was selected for these in vivo studies based on ex vivo efficacy and its blood brain 
barrier penetrance.46 These mice were treated for 20 days, or until they displayed behavior 
consistent with having MB (head tilt, hunched posture, ataxia, weight loss), at which time 
the mice were killed and their brains collected for further analyses. We noted that 
orthotopically grown MBs were significantly smaller in carnosate treated mice relative to 
vehicle treated mice (Figures 5a and b). These smaller residual tumors had decreased 
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numbers of proliferating cells, as determined by PCNA immunostaining (Figure 5c, 
Supplementary Figure S5A), and decreased numbers of SOX2+ cells (Figure 5d, 
Supplementary Figure S5B). These results appear distinct from our ex vivo experiments in 
which carnosate did not affect culture growth (Figure 3e, Supplementary Figure S3F). We 
speculate that the effects we see on MB cell proliferation in vivo are indirect, resulting from 
loss of the MPCs that drive bulk tumor growth. Likely, similar effects were not observed ex 
vivo because of the significantly reduced time such cultures were exposed to carnosate.
To determine the WNT dependence of MPCs in vivo, we implanted MB tissue into the 
flanks of mice and treated them with carnosate or vehicle once tumor growth was palpable. 
Carnosate significantly reduced the expression of WNT target genes, but not SHH target 
genes, in these tumors (Figure 5e), and reduced the numbers of SOX2+ cells (Figure 5f, 
Supplementary Figure S5C). Consistent with carnosate treatment reducing the number of 
MPCs, MB tissue from the carnosate-treated primary tumors also displayed significantly 
reduced ability to initiate new tumors when similar numbers of viable donor cells were 
reimplanted into recipient mice (Figure 5g). We also reimplanted carnosate-treated MB 
tissue from donor mice orthotopically into naïve recipient mice, and monitored their MB 
symptom-free survival. Consistent with carnosate treatment reducing MB propagation, mice 
harboring carnosate-treated tumor tissue exhibited significantly increased MB symptom-free 
survival over those that received MB tissue from vehicle-treated donors (Figure 5h).
DISCUSSION
The WNT signaling pathway regulates multiple aspects of stem cell function. Indeed, WNT 
ligands play key roles in neuronal stem cell self-renewal,31 symmetric division,47 
pluripotency48 and tumor initiation in cancer stem cells.31,49 We show here that the self-
renewal of multipotent, SOX2+-enriched SCs, which ultimately drive the growth of Trp53-
deficient SHH-subgroup MB, is dependent on WNT activity. This conclusion is based on 
inhibiting several components of the canonical WNT signaling pathway, using both 
molecular genetic and small-molecule inhibitors (Supplementary Figure S6). Further, we 
show that a small-molecule WNT inhibitor is able to reduce the number of SOX2+ cells, 
tumor initiation and tumor growth in vivo, increasing the overall survival of mice harboring 
Trp53-deficient SHH-subgroup MB.
Our Trp53-deficient SCs had reduced expression of SHH biomarkers relative to primary MB 
tissue, which is likely why they were resistant to SMO inhibitors.50 However, these cultures 
expressed both WNT ligands and biomarkers associated with an activated WNT signaling 
pathway. Consistent with MPC self-renewal being WNT ligand-dependent, a PORCUPINE 
inhibitor, which reduces WNT ligand activity,38 or overexpression of DKK1, which 
attenuates WNT co-receptor activation,36 prevented SCs self-renewal. The self-renewal of 
Trp53-deficient SCs also required canonical β-CATENIN/TCF activity, as knockdown of β-
Catenin, overexpression of dnTCF3, or four distinct small-molecule inhibitors of this WNT-
dependent transcriptional complex, inhibited self-renewal. Based on the sensitivity of these 
cultures to these mechanistically distinct small molecule and molecular genetic regulators of 
WNT signaling, we suggest that the MPC-enriched cultures elaborate a WNT ligand-
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dependent activation of canonical β-CATENIN/TCF signaling, which ultimately drives SC 
self-renewal.
It was previously suggested that WNT signaling attenuates the growth of SHH-subgroup 
MB.43–45 This work showed that the repressive effect of WNT activity on SHH-subgroup 
MB was indirect, via downregulation of SHH signaling. The major difference between these 
previous studies and our work is that we use a Trp53-deficient mouse model of MB. 
Consistent with this previous work, we show that SCs expressing WT Trp53 do not express 
high levels of WNT biomarkers, are not sensitive to WNT inhibition and do not self-renew 
in a WNT-dependent manner. However, we also show that reducing P53 activity in these WT 
Trp53 cultures increased WNT activity and that overexpression of Trp53 in 
Ptch1−/−;Trp53−/− SCs reduced WNT activity. Together, these results suggest that loss of 
Trp53 expression modulates the WNT dependence of Ptch1 mutant-driven MB. Similarly, it 
was previously suggested that P53 can repress canonical WNT signaling in several tumor 
types. In some tumors, such as neuroblastoma and breast cancer, this regulation was shown 
to occur via the transcriptional activation of specific micro-RNAs.51,52 While in colorectal 
cancer, loss of TRP53 activates WNT signaling via BONE MORPHOGENIC PROTEIN 
signaling.53
TRP53 status is the most important risk factor of SHH-subgroup MB patients.13,54,55 These 
patients, who tend to be children with germline TRP53 mutations, exhibit a significantly 
reduced 5-year survival rate.56 Further, clinical trials of vismodegib noted reduced 
progression-free survival of SHH-subgroup MB patients deficient in P53 activity.13 Our 
findings suggest a model in which loss of Trp53 results in the emergence of a vismodegib 
resistant, WNT-dependent population of MPCs. We further suggest that this population of 
WNT-dependent MPCs might underlie the poor outcome and relative vismodegib resistance 
of SHH-subgroup patients deficient in TRP53. Indeed, a similar model in which WNT-
dependent basal cell carcinoma propagating cells drive bulk SHH-dependent basal cell 
carcinoma growth has been described.57,58 Although the translational relevance of our 
findings using mouse models of MB are not yet known, we speculate that a therapeutic 
approach using WNT inhibitors would improve the outcome of TRP53-deficient SHH-
subgroup patients. Importantly, such patients would likely benefit most from the use of 
combination therapy that also includes conventional chemotherapy or one of the SMO 
inhibitors now in clinical trials. Such a therapeutic strategy would inhibit the growth of the 
bulk tumor by targeting the rapidly dividing MB cells as well as target the MPCs that are 
resistant to such agents.59
MATERIALS AND METHODS
MPC enrichment and assay
MB tissue was enzymatically and mechanically digested using the Papain Dissociation 
System (Worthington, Lakewood, NJ, USA).60,61 The resulting cell suspensions were grown 
ex vivo in Neurobasal serum-free medium containing 1% Glutamax, 2% B27, 1% N2, 
epidermal growth factor (25 ng/ml), fibroblast growth factor (25 ng/ml) and Pen-Strep 
(Invitrogen, Frederick, MD, USA) and allow to form spheres for up to 10 days. For analysis 
by immunocytochemistry, SCs were plated on poly-L-lysine-coated glass chamber slides 
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(Millipore, Billerica, MA, USA) in the medium described above or in Neurobasal medium 
containing 2% fetal bovine serum for 6 days, essentially as previously described.62 All 
primary antibodies including: SOX2 #ab97959 (Abcam, Cambridge, UK), PCNA #2586, 
GFAP #12389, CNPASE #5664, β3-TUBULIN #5568, NESTIN #4760, 
NEUROFILAMENT-L #2837 (Cell Signaling, Danvers, MA, USA) were used according to 
their manufacturer’s instructions. For analyses by flow cytometry, cell suspensions from SCs 
or tumor tissues were incubated in Cytofix/Cytoperm solution (Becton & Dickinson, 
Franklin Lakes, NJ, USA) prior to staining with the corresponding fluorescent-conjugated 
antibody: SOX2 #656103, PCNA #307909 (BioLegend, San Diego, CA, USA), and 
CLEAVED CASPASE-3 #9669 (Cell Signaling). Fluorescence activated cell sorting (FACS) 
data were acquired using a BD CANTO II FACS (Becton & Dickinson) and analyzed using 
DiVa6 software.
Cell and molecular biology
Plasmids expressing a dominant-negative TCF3 construct (dnTCF3),63 DKK1 (Addgene, 
Cambridge, CA, USA), Trp53 (Takara, Mountain View, CA, USA), a dominant-negative P53 
(dnTrp53) (Takara) or siRNA smart pools (Dharmacon, Lafayette, LA, USA) were 
transfected into SCs using Lipofectamine 2000 (Invitrogen). Cell viability was monitored by 
the reduction of 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide to 
formazan,64 or by trypan blue exclusion when evaluating the number of viable cells prior to 
sphere formation assays, FACS analysis or engraftment in vivo. Secondary sphere formation 
was determined using equal numbers of viable cells, from treated primary SCs, to form 
spheres in 8 days. Total RNA was Trizol (Invitrogen) extracted and the expression of the 
indicated genes determined using quantitative real-time PCR (RT–qPCR) and Taqman 
probes (Invitrogen), followed by normalization to the expression of Gapdh.65 The efficacy of 
WNT antagonists was validated using a mycoplasma tested cell line and containing a 
TCF/LEF luciferase reporter gene, HEK 293 STF (ATCC, Manassas, VA, USA), treated 
with 10 mM LiCl and 10 mg/ml WNT3a, and normalized to protein concentration. For 
Ctnnb1 sequencing cDNA was prepared from total RNA extracted from SCs-1, 2, 3. The 
region of β-Catenin (Ctnnb1) encoding exon 3 was sequenced and compared to WT. Primer 
sequences used were Ctnnb1 Fw: 5′-CGC TGCGTGGACAATGGCTA-3′ and Ctnnb1 Rv: 
5′-CGTGTGGCAAGTTCCGCGTC-3′. Sequence alignment was performed using Ape 
software.
Mouse work
All mouse work was conducted in accordance with protocols approved by the Institutional 
Animal Care and Use Committee at the University of Miami. Ptch1tm1Mps/J66 and 
B6.129S2-Trp53tm1Tyj/J67 mice (Jackson laboratory, Bar Harbor, ME, USA) were mated to 
generate a breeding colony. Spontaneous tumors Ptch1−/−;Trp53+/+ or Ptch1+/− ;Trp53+/− 
were expanded and maintained in 6-week-old male CD1-Foxn1nu mice as allografts (Charles 
River Laboratories, Worcester, MA, USA). For orthotopic studies, 100 000 viable cells were 
resuspended in 3 µl final volume and implanted into the cerebella of 6-week-old male CD1-
Foxn1nu mice using the stereotaxic coordinates 2 mm posterior to lambda, 2 mm lateral to 
the middle line and 2 mm deep. Treatment was started 2 days after implantation. The same 
coordinates and final volume were used to implant 10 000 viable cells for symptom-free 
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survival studies. For flank treatments, 1 000 000 viable cells were subcutaneously implanted 
into 6-week-old male CD1-Foxn1nu mice and treatment started once the tumors reached a 
size of approximately 200 mm3. Mouse tissues were fixed in formalin prior to be stained. 
For in vivo engraftment studies, the indicated numbers of viable cells from residual tumors 
were implanted into the flanks of 6-week-old male CD1-Foxn1nu mice. For all in vivo 
studies, 50 µl of 50 mg/kg vismodegib (Selleckchem, Houston, TX, USA) or 10 mg/kg 
carnosate (Enzo, Farmingdale, NY, USA) both dissolved in dimethyl sulfoxide and were 
administrated daily via intra-peritoneal injection.
Statistical analysis
For our ex vivo analyses, the results shown represent the mean of at least three independent 
experiments ± s.e.m. For in vivo analyses, the results shown represent the mean and s.e.m. of 
at least six mice. For IHC quantification, the results shown represent the mean and s.e.m. of 
at least six fields from three different tumors. Sample sizes were chosen based on similar 
well-characterized experiments to ensure adequate power to detect a pre-specified effect 
size. Mice were randomly distributed to different treatments and the investigator blinded to 
the assignment until final tumor analyses. For symptom-free survival analysis, those mice 
that did not show tumors as per hematoxylin eosin staining 60 days after experiment 
initiation were excluded from the analyses. Significance in multiple group comparisons was 
determined using a one-way analysis of variance followed by a post-hoc Student–Newman–
Keuls analysis. Two sample analyses were determined using a one-tailed Student’s t-test. 
Data generated showed normal distribution with similar variances, and analysis was 
completed assuming equal variances. Statistical significance was reached when P < 0.05. 
The significance of tumor frequency was determined using a χ2 test, and statistically 
significance determined when α < 0.05. Survival significance was calculated using a Log-
rank (Mantel–Cox) test and statistically significance reached when P < 0.05.
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Figure 1. 
Medulloblastoma sphere cultures display stem cell properties. (a) The expression of the 
indicated progenitor cell biomarkers, from three independently derived Trp53-deficient MB 
sphere cultures (SC-1, 2 and 3) and two primary MBs (MB-A and MB-B), was determined 
and then normalized to that of MB-A. (b) SCs were immunostained for neuronal progenitor 
biomarkers (NESTIN and β3-TUBULIN). (c) The level of SC pluripotency was determined 
by examining the biomarkers GLIAL FRIBRILLARY ACIDIC PROTEIN (GFAP), 
NEUROFILAMENT-LARGE (NF-L) or CYCLIC-NUCLEOTIDE-
PHOSPHODIESTERASE (CNPASE). Representative images of immunostained SC-2 are 
shown. (d) The indicated numbers of viable SC-2 cells were implanted subcutaneously into 
the flanks of immunocompromised mice. The frequency and number of tumor engraftments 
is shown. (e) The percentage of SOX2+ cells in MB flank tumors and SCs was determined 
by FACS analysis.
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Figure 2. 
The self-renewal of medulloblastoma sphere cultures is dependent on WNT activity. (a) A 
heat map representing the relative gene expression of SHH (Gli1, Gli2, Gli3, Ptch2, Smo, 
Hhip, Sufu, Boc, Cdo) and WNT pathway-related genes (Axin1, Axin2, Lgr5, Ctnnb1, 
Dkk1, Ddx3, Lef1, Porcn), as determined in the indicated Trp53-deficient SCs and Trp53-
deficient MB tissues (MB-A and MB-B). The color scale was calculated using Log2 
transformed gene expression data normalized to their expression in MB-A. (b) SC-2 were 
transfected with the indicated siRNA smart pools, and the expression of the indicated genes 
determined 72 h later. (c) The ability of SC-2 to form secondary spheres 72 h after 
transfection with the indicated siRNA smart pool was determined. (d) SC-2 were transfected 
with a plasmid expressing a dnTCF3 construct or a control plasmid (pCS2), and the 
expression of the indicated genes determined 48 h later. (e) The ability of SC-2 to form 
secondary spheres was determined 48 h after transfection with a dnTCF3 expression plasmid 
or control plasmid (pCS2). (f) SC-2 was transfected with a plasmid expressing a dnTCF3 
construct or control plasmid (pCS2) and cell viability determined 5 days later using an MTT 
reduction assay. (g) SC-2 was transfected with a plasmid expressing DKK1 or control 
plasmid (pCS2) and the expression of WNT target genes determined. (h) The ability of SC-2 
to form secondary spheres was determined 48 h after transfection with a plasmid expressing 
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DKK1 or control plasmid (pCS2). (i) SC-2 was transfected with a plasmid expressing DKK1 
or control plasmid (pCS2) and cell viability determined 5 days later using an MTT reduction 
assay. Results were normalized to that from pCS2 transfected cultures unless otherwise 
indicated. MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide.
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Figure 3. 
Small-molecule WNT inhibitors attenuate the self-renewal of medulloblastoma sphere 
cultures. (a) SC-2 were treated with the indicated concentrations of the PORCUPINE 
inhibitor LGK974, and the expression of the indicated genes determined 72 h later. (b) The 
ability of SC-2 to form secondary spheres was determined following incubation (72 h) with 
the indicated concentrations of LGK974. (c) SC-2 were incubated with the indicated 
concentrations of LGK974, and cell viability determined 5 days later using an MTT 
reduction assay. (d) The ability of SC-2 to form secondary spheres was determined 
following incubation (24 h) with the indicated concentrations of TCF/β-CATENIN inhibitors 
(carnosate, CCT-031374 hydrobromide [CCT], ICG-001 [ICG] or PKF-115-584 [PKF]). (e) 
SC-2 were incubated for 72 h with the indicated concentrations of TCF/β-CATENIN 
inhibitors, and cell viability determined 5 days later using an MTT reduction assay. (f) SC-2 
were treated with the indicated TCF/β-CATENIN inhibitors for 24 h. The expression of the 
indicated genes was determined. Results were normalized to dimethyl sulfoxide control. 
MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide.
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Figure 4. 
MPC enriched cultures expressing wild-type Trp53 are not WNT-dependent. (a) The 
expression of the indicated genes was determined in Ptch1−/−;Trp53−/− or Ptch1−/−;Trp53+/+ 
SCs, and normalized to the data from Ptch1−/−;Trp53−/− cultures. (b) SC cultures were 
treated with 25 µM carnosate for 24 h, and the expression of the indicated WNT target genes 
determined. (c) The ability of the SCs to form secondary spheres, following incubation (24 
h) with the indicated concentrations of carnosate, was determined. (d) The indicated SCs 
were incubated for 3 days with the various concentrations of carnosate, and cell viability 
determined 5 days later using an MTT reduction assay. The results were normalized to those 
from the dimethyl sulfoxide control. (e) SCs were transfected with a plasmid expressing a 
dnTCF3 construct or a control plasmid (pCS2), and the expression of the indicated WNT 
target genes determined 48 h later. (f) The ability of SCs to form secondary spheres was 
determined 48 h after transfection with plasmids expressing dnTCF3, a control plasmid 
(pCS2) or GFP. Results were normalized to those from the pCS2 control. (g) Ptch1−/
−;Trp53−/− SCs were transfected with plasmids expressing wild-type P53 (pCMV-Trp53), or 
an enhanced green fluorescent protein (EGFP) (pCMV-EGFP) control vector, and the 
expression of the indicated genes determined 72 h later. (h) Ptch1−/−; Trp53+/+ SCs were 
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transfected with plasmids expressing dominant negative P53 (pCMV-dnTrp53) or EGFP 
(pCMV-EGFP), and the expression of the indicated genes determined 72 h later. The results 
were normalized to those from the EGFP expressing cultures. (i) Ptch1−/−;Trp53+/+ SCs 
were incubated with the P53/MDM2 inhibitor Pifithrin-α (PFT-α) for 24 h, and the 
expression of the indicated genes determined. The results were normalized to those from the 
dimethyl sulfoxide control. MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium 
bromide.
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Figure 5. 
The propagation and growth of Trp53-deficient, SHH-subgroup medulloblastoma is WNT-
dependent. Trp53 mutant, Ptch1-driven MB tissue, which had never been cultured ex vivo, 
was orthotopically implanted into the cerebellum of immunocompromised mice. These mice 
were then treated with carnosate or vehicle for 20 days, or until they developed MB 
symptoms. The mice were then killed and their brains collected. (a) Representative 
hematoxylin eosin staining of orthotopic MB tissue from a carnosate or vehicle-treated 
mouse is shown. (b) The volume of residual orthotopic tumors from these mice was 
calculated, and the mean volume and s.e.m. shown. (c) The residual orthotopic tumors from 
these mice were immunostained for the proliferation biomarker PCNA, and the numbers of 
PCNA+ cells quantified and normalized to total cell number per field (%). (d) The residual 
orthotopic tumors from these mice were immunostained for the MPC biomarker SOX2, and 
the numbers of SOX2+ cells quantified and normalized to total cell number per field (%). (e) 
MB tumor tissue was subcutaneously implanted into the flanks of immunocompromised 
mice, and treated daily with of carnosate, or vehicle control, for 8 days. The expression of 
the indicated genes in residual flank tumors was then determined. (f) The enrichment of 
SOX2+ cells in residual flank tissue, from carnosate or vehicle-treated mice, was determined 
by FACS analysis. (g) The indicated number of viable cells from residual MB tissue was 
transplanted into additional immunocompromised mice, and the frequency of tumor 
engraftment determined. (h) Equal numbers of viable cells from residual flank MB tissue 
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were implanted into the cerebellum of additional immunocompromised mice, and MB 
symptom-free survival monitored for 60 days. Results were normalized to vehicle control.
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